SCHEDULE 13D
SCHEDULE 13DSchedule 13D ownership disclosure
SpyGlass Pharma, Inc.
Common Stock, $0.00001 par value per share · CUSIP: 85220G109
Event date: 2026-02-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- New Enterprise Associates 17, L.P.Reported CIK 0001768564
Shares: 7,392,301.00 · Class: 22.2%
- NEA Partners 17, L.P.Reported CIK 0001796820
Shares: 7,392,301.00 · Class: 22.2%
- NEA 17 GP, LLCReported CIK 0001796821
Shares: 7,392,301.00 · Class: 22.2%
- New Enterprise Associates 16, L.P.Reported CIK 0001694560
Shares: 7,392,301.00 · Class: 22.2%
- NEA Partners 16, L.P.Reported CIK 0001712881
Shares: 7,392,301.00 · Class: 22.2%
- NEA 16 GP, LLCReported CIK 0001712882
Shares: 7,392,301.00 · Class: 22.2%
- Forest BaskettReported CIK 0001277631
Shares: 7,392,301.00 · Class: 22.2%
- Ali BehbahaniReported CIK 0001613867
Shares: 7,393,823.00 · Class: 22.2%
- Carmen ChangReported CIK 0001746342
Shares: 7,392,301.00 · Class: 22.2%
- Anthony A. Florence, Jr.Reported CIK 0001559827
Shares: 7,392,301.00 · Class: 22.2%
- Mohamad H. MakhzoumiReported CIK 0001630226
Shares: 7,392,301.00 · Class: 22.2%
- Edward T. MathersReported CIK 0001328625
Shares: 6,035,038.00 · Class: 18.1%
- Scott D. SandellReported CIK 0001237289
Shares: 7,392,301.00 · Class: 22.2%
- Paul WalkerReported CIK 0001553150
Shares: 7,392,301.00 · Class: 22.2%
- Rick YangReported CIK 0001851328
Shares: 6,035,038.00 · Class: 18.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001072613-26-000183
- Form type
- SCHEDULE 13D
- Filer
- New Enterprise Associates 17, L.P.
- CIK
- CIK 1768564
- Filed
- Feb 13, 2026
- Reporting period
- Feb 09, 2026
- Description
- Schedule 13D beneficial ownership